Victoria Werth, MD, a Professor of Dermatology at the University of Pennsylvania in Philadelphia and Advisor to Lupus Research Alliance’s clinical affiliate Lupus Therapeutics, highlights some key clinical and basic science studies on lupus presented at the 2025 American College of Rheumatology (ACR) Meeting in Chicago, IL, including the Phase 2 PAISLEY-SLE and PAISLEY long-term extension studies which showed sustained efficacy and consistent safety for up to four years among patients with severe systemic lupus taking deucravacitinib (Sotyktu, Bristol Myers Squibb). She also discusses biomarker results from a study of deucravacitinib in patients with cutaneous manifestations of lupus, granzyme B as a regulator of interferon alpha production cutaneous lupus, the pipeline, plus more.
